These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24010883)

  • 21. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD; Martineau P; Bryanton M; Lix LM
    Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study.
    Kung AW; Fan T; Xu L; Xia WB; Park IH; Kim HS; Chan SP; Lee JK; Koh L; Soong YK; Soontrapa S; Songpatanasilp T; Turajane T; Yates M; Sen S
    BMC Womens Health; 2013 Feb; 13():7. PubMed ID: 23410131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone mineral density enhances use of clinical risk factors in predicting ten-year risk of osteoporotic fractures in Chinese men: the Hong Kong Osteoporosis Study.
    Bow CH; Tsang SW; Loong CH; Soong CS; Yeung SC; Kung AW
    Osteoporos Int; 2011 Nov; 22(11):2799-807. PubMed ID: 21234548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of FRAX in clinical practice according to sex and osteoporosis definitions: the Manitoba BMD registry.
    Leslie WD; Majumdar SR; Morin SN; Lix LM; Schousboe JT; Ensrud KE; Johansson H; McCloskey EV; Kanis JA
    Osteoporos Int; 2018 Mar; 29(3):759-767. PubMed ID: 29404625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fracture risk assessment tool (FRAX) and for the diagnosis of osteoporosis in Japanese middle-aged and elderly women: Chiba bone survey.
    Oka R; Ohira M; Suzuki S; Yoshida T; Koide H; Tanaka T; Tatsuno I
    Endocr J; 2018 Feb; 65(2):193-202. PubMed ID: 29151451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteoporosis Management in a Real Clinical Setting: Heterogeneity in Intervention Approach and Discrepancy in Treatment Rates when Compared with the NOGG and NOF Guidelines.
    Kyriakos G; Vidal-Casariesgo A; Quiles-Sánchez LV; Urosa-Maggi JA; Calleja-Fernández A; Hernández-Moreno A; Ballesteros-Pomar MD; Cano-Rodriguez I
    Exp Clin Endocrinol Diabetes; 2016 Sep; 124(8):466-473. PubMed ID: 27219881
    [No Abstract]   [Full Text] [Related]  

  • 27. Added clinical use of trabecular bone score to BMD for major osteoporotic fracture prediction in older Chinese people: the Mr. OS and Ms. OS cohort study in Hong Kong.
    Su Y; Leung J; Hans D; Aubry-Rozier B; Kwok T
    Osteoporos Int; 2017 Jan; 28(1):151-160. PubMed ID: 27725999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vertebral fracture assessment by dual-energy X-ray absorptiometry along with bone mineral density in the evaluation of postmenopausal osteoporosis.
    Shetty S; John B; Mohan S; Paul TV
    Arch Osteoporos; 2020 Feb; 15(1):25. PubMed ID: 32095943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is lower income associated with an increased likelihood of qualification for treatment for osteoporosis in Canadian women?
    Brennan SL; Leslie WD; Lix LM
    Osteoporos Int; 2014 Jan; 25(1):273-9. PubMed ID: 23907573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study.
    Rubin KH; Rothmann MJ; Holmberg T; Høiberg M; Möller S; Barkmann R; Glüer CC; Hermann AP; Bech M; Gram J; Brixen K
    Osteoporos Int; 2018 Mar; 29(3):567-578. PubMed ID: 29218381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asia-pacific consensus on osteoporotic fracture prevention in postmenopausal women with low bone mass or osteoporosis but no fragility fractures.
    Huang CF; Chen JF; Reid IR; Chan WP; Ebeling PR; Langdahl B; Tu ST; Matsumoto T; Chan DC; Chung YS; Chen FP; Lewiecki EM; Tsai KS; Yang RS; Ang SB; Huang KE; Chang YF; Chen CH; Lee JK; Ma HI; Xia W; Mithal A; Kendler DL; Cooper C; Hwang JS; Wu CH
    J Formos Med Assoc; 2023; 122 Suppl 1():S14-S20. PubMed ID: 36775679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining strategies for improving the identification and management of osteoporosis in the primary care setting.
    Miller PD
    Int J Fertil Womens Med; 2003; 48(6):261-72. PubMed ID: 15646396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct comparison of eight national FRAX® tools for fracture prediction and treatment qualification in Canadian women.
    Leslie WD; Brennan SL; Lix LM; Johansson H; Oden A; McCloskey E; Kanis JA
    Arch Osteoporos; 2013; 8():145. PubMed ID: 23929269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.
    Su Y; Lai FTT; Yip BHK; Leung JCS; Kwok TCY
    Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postmenopausal osteoporosis: fracture risk and prevention.
    Kaunitz AM; McClung MR; Feldman RG; Wysocki S
    J Fam Pract; 2009 Nov; 58(11 Suppl Postmenopausal):S1-6. PubMed ID: 19891943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure in the application of fragility fracture prevention guidelines.
    Elvey MH; Pugh H; Schaller G; Dhotar G; Patel B; Oddy MJ
    Ann R Coll Surg Engl; 2014 Jul; 96(5):381-5. PubMed ID: 24992424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnitude of fragility fracture risk in the very old--are we meeting their needs? The Newcastle 85+ Study.
    Duncan R; Francis RM; Jagger C; Kingston A; McCloskey E; Collerton J; Robinson L; Kirkwood TB; Birrell F
    Osteoporos Int; 2015 Jan; 26(1):123-30. PubMed ID: 25224291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BMD, clinical risk factors and their combination for hip fracture prevention.
    Johansson H; Kanis JA; Oden A; Johnell O; McCloskey E
    Osteoporos Int; 2009 Oct; 20(10):1675-82. PubMed ID: 19291344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.